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bbk@apk.molbio.ku.dkWe report the solution structure of human prolactin determined by NMR
spectroscopy. Our result is a significant improvement over a previous
structure in terms of number and distribution of distance restraints,
regularity of secondary structure, and potential energy. More significantly,
the structure is sufficiently different that it leads to different conclusions
regarding the mechanism of receptor activation and initiation of signal
transduction. Here, we compare the structure of unbound prolactin to
structures of both the homologue ovine placental lactogen and growth
hormone. The structures of unbound and receptor bound prolactin/
placental lactogen are similar and no noteworthy structural changes occur
upon receptor binding. The observation of enhanced binding at the second
receptor site when the first site is occupied has been widely interpreted to
indicate conformational change induced by binding the first receptor.
However, our results indicate that this enhanced binding at the second site
could be due to receptor–receptor interactions or some other free energy
sources rather than conformational change in the hormone. Titration of
human prolactin with the extracellular domain of the human prolactin
receptor was followed by NMR, gel filtration and electrophoresis. Both
binary and ternary hormone–receptor complexes are clearly detectable by
gel filtration and electrophoresis. The binary complex is not observable by
NMR, possibly due to a dynamic equilibrium in intermediate exchange
within the complex. The ternary complex of one hormone molecule bound
to two receptor molecules is on the contrary readily detectable by NMR.
This is in stark contrast to the widely held view that the ternary prolactin–
receptor complex is only transiently formed. Thus, our results lead to
improved understanding of the prolactin–prolactin receptor interaction.
q 2005 Elsevier Ltd. All rights reserved.
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Prolactin (PRL) is a 23 kDa four-a-helix bundle
protein hormone secreted by the anterior pituitary
gland. More than 300 different biological functions
have been attributed to PRL,1 the major ones being
induction of differentiation and growth in mam-
mary epithelia and stimulation of milk protein
secretion. The biological activities of PRL are
mediated by its binding to the PRL receptor
(PRLR) in a one-to-two complex and regulated by
tertiary structural properties. The sequence of
events, high-affinity binding to the first subunit of
the receptor, association of a lower-affinity subunit
into a ternary complex, followed by an intracellular
cross-phosphorylation cascade, is common to the
members of this cytokine receptor family. Based ond.









Dihedral angle restraints (TALOS)
F 176
J 144
Residual dipolar couplings 81
B. Restraints violations
NOE violationsO0.3 A˚ 6
Largest NOE violation (A˚) 0.34
NOE RMSD 0.03G0.00
Dihedral angle violationsO58 0
Largest dihedral angle violation (deg.) 3.88
Dihedral angle RMSD 0.18G0.05
RDC violationsO1 Hz 0
Largest RDC violation (Hz) 0.99
R-factor for RDC (%) 5.1G0.2
C. Ramachandran plot
Most favored regions (%) 87.4
Additionaly allowed regions (%) 11.9
Structure of Prolactin 811fluorescence resonance energy transfer studies
binding of the first receptor subunit to hPRL has
been hypothesized to induce a conformational
change in the hormone that increases the affinity
for binding of the second receptor subunit.2 Site 2 is
thus considered not competent for receptor binding
in the free hormone.2
PRL is a member of the long-chain cytokine
family and is closely related to growth hormone
(GH) and placental lactogen (PL), with both of
which it shares 23% sequence identity. Whereas GH
is able to bind to the GH receptor (GHR) and for
primates GH to PRLR, PRL (and non-ruminant PL)
only binds PRLR. Ruminant PL may also bind
heterodimers of homologous PRLR and GHR.3 The
structural basis for the cross-reactivity observed
between primate GH and PRLR but not between
PRL and GHR is of fundamental importance for a
full understanding of PRL biology. Binding of GH
to GHR, of primate GH to PRLR and of PRL to
PRLR has been studied thoroughly by site-directed
mutagenesis, and residues contributing to the
binding energy have been identified.4–9 Different
subsets of residues define the binding surfaces in
each hormone–receptor complex.
Several other facets of prolactin biology can
benefit from knowledge of an accurate, high-
resolution solution structure. A precise determi-
nation of the 3D structure is an important platform
for the design of molecules with agonistic and
antagonistics properties,10–12 as this certainly will
enhance the molecular understanding and guide
the design. Moreover, an N-terminal fragment of
both rat PRL13 and of human PRL (hPRL),14,15 the
16K-PRL, has been shown to be a potent anti-
angiogenic factor either in vitro or in vivo that
significantly reduces tumor growth. Comparative
structural studies may reveal important insight into
the functional determinants of this process.
Recently, hPRL was shown to interact with cyclo-
philin B, which facilitates transport of hPRL to the
nucleus where the hPRL–cyclophilinB complex
induces cell growth and proliferation.16,17
In order to elucidate the detailed molecular
interactions between PRL and its diverse inter-
acting partners, an accurate, high-resolution
structure is essential. Here, we report a high-
resolution NMR solution structure of unbound
hPRL and studies of its interaction with the
extracellular domain of human prolactin receptor.
A key finding is that our results do not support
recent findings of conformational changes in the
hormone upon receptor binding. Our data
challenge conventional wisdom and establish a
sound structural platform for further studies on
PRL interactions.Generously allowed regions (%) 0.6
Disallowed regions (%) 0.1
D. RMSD of atomic positions (A˚)a
Backbone 0.32G0.05
Heavy atoms 0.85G0.04
a Calculated as RMSD to the mean structure for residues in the
four long helices (residues 15–43, 78–103, 111–137, and 161–193).Results
Assignment of prolactin at pH 8.0
From the set of recorded triple-resonance spectra,backbone resonance assignments for 140 residues
could be obtained. From 13C-NOESY-HSQC and
HCCH-TOCSY spectra side-chain resonances for
182 residues could be assigned. For the 42 residues
for which no backbone assignments were obtained,
the side-chain assignments were based on NOEs in
combination with preliminary structures. For 17
residues (Leu15, Gly47, Gly49, Thr52, Cys58, His59,
Glu67, Gln77, Gln106, Glu110, Glu140, Gly152,
Pro154, Ser155, Gln157, Glu161, and His195) no
assignments were obtained. These residues are
mainly located in loop regions. In total, 83% of all
backbone, aliphatic and aromatic protons were
assigned.Structure determination
The solution structure of human PRL at pH 8 and
37 8C was solved on the basis of a total of 2550
restraints (Table 1). A final set of 200 structures was
calculated using X-plor-NIH and 20 structures with
the lowest energy and no restraint violations
larger than 0.4 A˚, 58, and 1 Hz for NOEs, dihedral
angles and residual dipolar couplings (RDCs),
respectively, were selected to represent the
structure. The backbone atoms for residues in the
four major a-helices of the 20 structures were
aligned with an RMSD to the mean structure of
0.32(G0.05) A˚ (Figure 1). The RMSD to the mean for
the backbone atoms of all residues in the structural
alignment is 1.7(G0.4) A˚.
Figure 1. Solution structure of human prolactin. (a) Stereo view of the ensemble of the 20 lowest energy structures of
1RW5 solved by NMR spectroscopy. The backbone atoms C, Ca, N of the four major a-helices (Leu15–Arg43, Lys78–
Arg103, Ala111–Val137, and Glu161–Ile193) were used for aligning the structures. (b) Ribbon representation of the lowest
energy structure with the helices labeled accordingly. To the left is seen the hormone from the side and to the right the
hormone is tilted 908 backwards and viewed from the bottom.
812 Structure of ProlactinSecondary structure
The secondary structure content of the ensemble
was calculated with DSSPcont.18 Four major
a-helices are present in the structure from Leu15
to Arg43 (helix 1), Lys78 to Arg103 (helix 2), Ala111
to Val137 (helix 3) and Glu161 to Ile193 (helix 4).
A short 310-helix is present from Thr60 to Ser62
(helix 1 0) and a short a-helix is present from Lys69 to
Gln74 (helix 1 00).
Tertiary structure
The core of the human PRL structure is made upby the four major a-helices that wind slightly
around each other (Figure 1). Inter-helical angles
are between 18.58 and 38.88. The helices group in
two antiparallel pairs, helix 1/helix 4 and helix
2/helix 3, each pair being packed more closely
together and with their helical axis more nearly
parallel as compared with the helices of the other
pair. The minor helices are found in the overhand
loop connection between helix 1 and helix 2. Helix
1 0 is tethered to helix 4 by a disulfide bond from
Cys58 (just before the beginning of helix 1 0) to
Cys174. A total of 32 NOEs between Ile55 to Leu63
to the rest of the molecule determine the orientation
of helix 1 0 to be nearly parallel with helix 2. The
     
Figure 2. Hormone–receptor interactions studies. (a) 1H,15N-TROSY-HSQC NMR spectra of 15N-hPRL with an
increasing amount of unlabeled hPRLR-ECD. On top of each spectrum is shown the 15N-hPRL:hPRLR-ECD
stoichiometry. (b) Gel filtration of hPRL:hPRLR-ECD samples in 25 mM Tris–HCl (pH 8.0), 150 mM NaCl run at ratios
0:1, 1:0.5, 1:1, 1:2, and 1:0. Absorption wasmeasured at 220 nm. (c) Extracts from the NMR samples of 15N-hPRL–hPRLR-
ECD complexes from (a) analyzed by native PAGE (top) and by SDS–PAGE (bottom). HMW, high molecular mass
markers (67 kDa and 140 kDa); LMW, lowmolecular mass markers (14.2 kDa, 20.1 kDa, 30.0 kDa, 43.3 kDa, 66.3 kDa and
96.4 kDa). In the top panel of both gels is listed the 15N-hPRL:hPRLR-ECD ratios of the samples. hPRLR-ECD runs at
higher molecular mass than expected due to the C-terminal His6-tag. The small band observed below the hPRL band in
the gel is due to incomplete reduction by DTT.
Structure of Prolactin 813conformation of helix 1 00 is well determined with a
RMSD value of 0.1 A˚ for the backbone atoms of the
six residues. The orientation of helix 1 00 is con-
strained by five NOEs to helix 2 and helix 4. The N-
terminal part of the protein is highly flexible relative
to the rest of the protein. The backbone confor-mations of Ile3–Gln12 are nevertheless fairly well
defined (RMSD value of 1 A˚), presumably owing to
the restricted conformational freedom conferred by
a disulfide bond between residues 4 and 11. The
C terminus is restricted by a disulfide bond
between residues 191 and 199, resulting in the
814 Structure of Prolactinpacking of the last five non-helical residues against
helix 4.Figure 3. Comparisons of prolactin structures. Struc-
tural alignment of two solution structures of human
prolactin. In green is the structure from this work (model
1 of the ensemble), in red the structure from PDB entry
1N9D (model 1 of the ensemble). Backbone atoms in the
four major helices (residues 15–43, 78–103, 111–137, and
161–193) were used for the alignment. The two structures
fit with an RMSD value of 3.8 A˚.Receptor binding studies
Titration of 15N-hPRL with increasing amounts of
the extracellular domain of the human prolactin
receptor (hPRLR-ECD) was followed by 15N,1H-
TROSY-HSQC spectra (Figure 2(a)). Addition of
increasing amounts of hPRLR-ECD to a solution of
15N-hPRL resulted in a gradual decrease in the
intensity of all peaks originating from the unbound
hormone. At 1.4 equivalents of receptor, the
intensity of most peaks had decreased beyond
detection. The decrease in intensity of the peaks
from the unbound hormone at molar ratios of 1:0,
1:0.5, and 1:1 samples did not reveal any clear
residue-specific variation (data not shown). The
positions of the peaks from the unbound hPRL are
insensitive to the relative amount of hPRLR-ECD,
and unbound hPRL must thus be in slow exchange
with the binary hormone–receptor complex on the
NMR time-scale. The failure to observe peaks from
the binary complex is likely the result of exchange
between an encounter complex and the fully
formed hormone–receptor complex at an inter-
mediate rate on the NMR time-scale. Further
addition of hPRLR-ECD resulted in the appearance
of a new set of peaks. The intensities of this new set
of peaks continue to increase up to a molar ratio of
1:3.5, which is the largest excess of receptor tested.
The positions of the peaks do not change
substantially with increasing amounts of hPRLR-
ECD. We presume that these peaks result from the
formation of a ternary complex of one hPRL bound
to two hPRLR-ECD. The results of the NMR
titration presented here are qualitative and do not
allow the determination of any thermodynamic or
kinetic parameters of the receptor binding
process.
The NMR titration results suggest that hPRL
binds to human PRLR-ECD in a one-to-two
stoichiometry. This is confirmed both by gel
filtration experiments with peaks corresponding to
49 kDa (1:1, KavZ0.13) andO75 kDa (1:2, KavZ0.03,
outside column capacity) (Figure 2(b)), and by
native PAGE, where bands at masses corresponding
to both the 1:1 and to the 1:2 complexes can be
identified (Figure 2(c)). This, together with the
receptor titration followed by NMR (Figure 2(a))
indicates that binding of the second receptor
molecule is stronger than previously anticipated.19
More likely, as recently suggested, the affinity for
the second receptor molecule increases significantly
when site 1 is occupied.2 Still, site 1 has a higher
affinity for hPRLR-ECD compared to the induced
affinity of site 2, as native PAGE or gel filtration at
sub-stoichiometric amounts of hPRLR-ECD and
hPRL observes no ternary complex. At more than
one equivalent of hPRLR-ECD, both binary and
ternary complexes are observed by native-PAGE
and gel filtration.DiscussionComparison to 1N9D
Alignment of the present structure at pH 8 (PDB
entry 1RW5) with the recently published solution
structure of human prolactin at pH 6.8, (PDB entry
1N9D),20 shows significant and unexpected differ-
ences in the geometry, arrangement and orientation
of the well-ordered parts of the molecule (Figure 3).
Especially distinct are the differences in the
regularity of the long helices and the orientation
of the short helix 1 00. Comparison of the two sets of
NOEs reveals fundamental differences. After reduc-
ing the NOE restraints by counting pairs of
methylene protons and pairs of methyl groups as
only one pseudo-atom, the number of NOE
restraints for 1N9D was reduced to 2462 and for
1RW5 it was reduced to 2117. Comparing these
reduced sets of NOEs showed only 328 NOEs
common to both. When comparing only NOEs
derived from a 13C-NOESY-HSQC of the aliphatic
region, only 142 of the 1365 NOEs reported between
aliphatic protons for the 1N9D structure are found
in the NOE set for the present structure. The conflict
is also readily apparent from an overlaid plot of the
Figure 4. Comparison of experimental data. (a) Overlay
of NOEs used for the structure calculation of 1RW5 (open
squares) and 1N9D (red dots). The Figure is symmetric
around the diagonal, except that the red dots are on top
above thediagonaland theopensquaresareon topbelowthe
diagonal. (b) Strip-plot of spin-systems Lys69 and Asp184
from13C-NOESY-HSQCrecordedatpH6.8 in100 mMNaCl.
The dotted circles indicate the positions of NOE cross-peaks
expected from the NOE restraint list of 1N9D.
Structure of Prolactin 815NOEs from the two structures (Figure 4(a)). In order
to ensure that structural changes with pH are not
the cause of this difference, a 3D-13C-NOESY-HSQC
was recorded on a sample of 13C,15N-hPRL in
100 mM NaCl at pH 6.8. This spectrum appears
similar to the 3D 13C-NOESY-HSQC recorded at pH
8 that was used for NOE assignment in the present
work. Although we have not performed an
exhaustive analysis of the pH 6.8 NOESY-HSQC
spectrum, none of the NOEs reported by Keeler
et al.,20 which we had not already found in our
analysis of the pH 8 spectrum, were found in the
spectrum recorded at pH 6.8 (Figure 4(b)).
The structure of 1N9D was analyzed by ProsaII,21
which is designed to identify erroneous structures.
Several parts of the 1N9D structure show positive
energies in the ProsaII analysis (data not shown).
Along with the energy calculations, ProsaII per-
forms a hide-and-seek test of a protein structure,
where a given structure is hidden in a 50,000
residue poly-protein. The amino acid sequence
corresponding to the hidden structure is dragged
along this poly-protein in order to find the
conformation with the lowest energy for the
sequence. In the case of the Cb–Cb energy, between
84 and 796 conformations accommodate the
sequence of hPRL better than the 20 structures of
1N9D. For comparison, no conformation accommo-
dates the hPRL sequence better than the 20
conformations of the present structure. Analysis of
the structure by WHAT-CHECK22 similarly
questions the accuracy of the 1N9D structure.
A summary of the WHAT-CHECK structural
Z-scores of both 1N9D and the present structure is
listed in Table 2. By comparison of the NOE
restraints deposited with 1N9D with the set of
NOEs of 1RW5, we conclude that the poor quality of
1N9D is caused by a very large number of mis-
assigned NOEs and the complete absence of
aromatic resonance assignments.
Evaluation of empirical potential energies using
the AMBER force field23,24 also reveals significant
differences between 1RW5 and 1N9D. The average
van der Waals energy for the 20 1N9D structures is
4585 kcal/mol, while the average value for the
structures comprising 1RW5 is 844 kcal/mol. The
average total potential energies are C1945 and
K2735 kcal/mol, respectively. Thus, the structuresTable 2. WHAT-CHECK structural Z-scores of hPRL
structures
PDB entry 1N9D 1RW5
2nd generation packing quality K3.055 K1.495
Ramachandran plot appearance K7.195 K1.376
Chi-1/chi-2 rotamer normality K6.890 0.117
Backbone conformation K11.282 K5.956
The Z-score expresses the number of standard deviations that a
score diverges from the expected value (the average from a set of
high quality structures). A positive Z-score indicates that the
score is better than average and a negative Z-score indicates that
the score is worse than average.
816 Structure of Prolactincomprising PDB entry 1N9D exhibit substantial
energetic strain compared to 1RW5.
Comparison to GH and PL
The structure of hPRL presented here is the first
accurate structural representation of an unmodified
lactogenic hormone in its unbound state. This
permits for the first time a detailed structural
comparison of the receptor bound ovine placental
lactogen (oPL) and unbound hPRL with bound and
unbound human GH (hGH). An overview of a
three-dimensional structural alignment between a
representative set of structures is listed in Table 3
and shown in Figure 5(a) and (b).
The three-dimensional structural alignment of
hPRL in its unbound state and oPL bound to the
extracellular domain of the prolactin receptor from
rat25 shows two highly similar structures with 89%
of the Ca atom aligning within 2 A˚ (Table 3). In
order to account for the increased affinity at site 2
when site 1 is occupied, it has been widely
speculated that prolactin may undergo substantial
structural changes upon binding to the prolactin
receptor.2 From the structural comparison of
unbound hPRL and bound oPL it appears, however,
highly unlikely that such a conformational change
occurs. Some electron density from residues of the
loop between helix 1 and helix 2 is missing in the
oPL-rPRLR crystal structure but structural align-
ment with the present structure does not suggest
substantial (O2 A˚) structural changes. Comparison
of helix crossing angles in the free form of hPRL and
in the bound form of oPL shows almost no
differences. The largest difference is a 48 change in
the orientation of helix 2 relative to helix 3. Also in
receptor-bound oPL, a short helix (residues Trp151–
Thr158) in the loop between helix 3 and 4 is
observed. At the similar position in hPRL, no
helix is observed. This is, however, in a part of
hPRL where many assignments are missing.
The structures of human GH in its unbound state,




PRL (%) 86.7 78.4 78.9
1RW5 (A˚) 1.69 1.53 1.56
GH (%) 91.0 92.2
Unbound (A˚) – 1.19 0.69
GH-GHR (%) 96.7
1:1 (A˚) – – 0.69
GH-GHR (%)
1:2 (A˚) – – –
GH-PRLR (%)
1:1 (A˚) – – –
PL-PRLR (%)
1:2 – – –
For each comparison, the Table gives the percentage of aligned Ca ato
of this alignment.PRLR have been described.7,26–28 In brief, no major
structural changes take place in hGH upon receptor
binding and all the structures of hGH are highly
similar, with one exception. In the loop between
helices 1 and 2, hGH forms a mini-helix (residues
Lys38–Asn47) when either unbound or bound to
one or two GHR molecules. This mini-helix has
been observed to adopt different orientations
depending on crystal packing, and shows high
plasticity in response to changing environment. It
rotates its orientation by 238 relative to the bundle
core when comparing the unbound to the bound
forms of hGH.26 In an affinity-matured form of
hGH, many mutated positions do not directly
interact with the receptor, but are positioned in
this mini-helix and may stabilize the otherwise
inherent flexibility of this region.26 Interestingly, in
the structure of hGH bound to hPRLR, this mini-
helix is unravelled at its N terminus and is only
three residues long (Figure 5(a) and (b)).
Compared to hGH, about 80% of the Ca atoms of
both hPRL and oPL align within 2 A˚ (Table 3).
A structural alignment of hPRL, oPL in complex
with rPRLR and hGH both unbound, bound to one
and two hGHR and bound to one hPRLR is shown
in Figure 5(a). The structures are aligned to hPRL by
their C, Ca and N atoms using a total of 120
residues. A sequential overview of the structural
alignment is shown in Figure 5(b).
Four clear differences between the structures are
evident from the alignments. Firstly, neither hPRL
nor oPL form the first mini-helix of hGH in the
beginning of the overhand loop between helices 1
and 2, although electron density is missing for some
of the loop-residues in oPL (Figure 5(a), I). Instead,
this loop region of lactogens aligns effectively with
the loop structure formed by hGH bound to hPRLR.
This clearly demonstrates the plasticity of this part
of hGH, as described earlier. Secondly, there are two
inserts in the apical end of the lactogenic hormones
clearly protruding, unrestricted, from the hormones
compared to the loop of GH that bends forward
(Figure 5(a), II). Thirdly, in the overhand loopR GH-PRLR PL-PRLR PRL
1:1 1:2
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Figure 5. Structural alignment of oPL, hGH and hPRL. (a) Ribbon representation of unbound hPRL (blue; PDB code,
1RW5), oPL bound to rPRLR (cyan; PDB code, 1F6F), unbound hGH (red; PDB code, 1HUW), hGH bound to hGHR (1:1,
magenta; PDB code, 1A22), hGH bound to hGHR (1:2, orange; PDB code, 3HHR) and hGH bound to hPRLR (1:1, green;
PDB code, 1BP3) aligned byMODELLER. I, Zoom on the GHmini-helix in the first overhand connection; II, zoom on the
first hPRL insert; III, zoom on the second overhand connection. GH, growth hormone; PL, placental lactogen; PRL,
prolactin; G, growth hormone receptor ECD; P, prolactin receptor ECD.(b) Text representation of a structural alignment
of hPRL (PDB code, 1RW5), hGH (PDB code, 1HUW), hGH:hGHR (1:1) (PDB code, 1A22), hGH:hPRLR (1:1) (PDB code,
1BP3), hGH:hGHR (1:2) (PDB code, 3HHR) and oPL:rPRLR (1:1) (PDB code, 1F6F). Identical residues are boxed red and
similar residues are in red on a white background. The helices of hPRL are indicated by boxes.
Structure of Prolactin 817
818 Structure of Prolactinbetween helix 3 and helix 4, GH has a short
structural insert in the beginning, whereas hPRL
and oPL have a structural insert at the end of this
loop (Figure 5(a), III). All three hormones align the
middle four residues (from hPRL:Tyr147–Trp150)
within 2.0 A˚. The differences may be consequences
primarily of the presence of a proline residue in
both oPL and hPRL (hPRL–Pro139) that is absent in
hGH, and which directs the hPRL and oPL loops in
the opposite direction to the hGH loop. Lastly, the
short helix observed in the loop between helix 3 and
helix 4 in receptor-bound oPL is not observed in any
of the hGH structures. These differences are
apparently not, except for the first loop structure
where GH forms a mini helix, important for
receptor binding, as no functional residues have
been identified within these loop structures. Why
these cytokines are so markedly different in their
loop positions disjoint from their receptor binding
sites remains to be investigated and fully under-
stood. The loop inserts of hPRLmay have to dowith
interactions to other proteins, as described above
(e.g. cyclophilin), or may even be important for the
generation of the smaller 16K fragment.Receptor binding
Despite the high level of structural homology of
the three-dimensional structures of hGH, oPL and
hPRL, different residues have been shown to be
responsible for providing the binding energy
and specificity of the interactions in the hGH–
hGHR complex, the hGH–hPRLR complex, the
oPL–rPRLR complex and the hPRL–hPRLR
complex.4,5,25,29,30 One significant difference
between hPRL and hGH is the relative stability of
the 1:2 complexes. For hGH the 1:2 complexes are
stable, whereas hPRL has been suggested to form
transient, unstable 1:2 complexes with homologous
complexes formed even less tightly than hetero-
logous complexes.19 This has led to the expectation
that homologous complexes dissociate rapidly due
to transient binding of the second receptor
molecule. Here, it is suggested that hPRL and
hPRLR–ECD forms tight 1:1 complexes, but also
that 1:2 complexes can be formed with a stability
that allows their detection by gel filtration. This is in
contrast to earlier studies on rainbow trout,31
bovine,32 ovine33 and rat PRL interacting with
PRLR,19,34 all pointing towards unstable homo-
dimerization reactions. To our knowledge, this is
the first demonstration by gel filtration techniques
of a stable 1:2 complex between a homologous
hormone–receptor pair of human prolactin. The
detections were done at micromolar concentrations
of protein, suggesting sub-micromolar binding
affinities. These findings are strongly supported
by a recent determination of KD1 and KD2 values by
surface plasmon resonance for each of the receptor
binding sites in hPRL. Both dissociation constants
are of the same order of magnitude and in the nano-
molar range.2 Also, as expected, all three differenttechniques applied here confirm the sequential
scenario of binding of two receptor molecules.
Binding site 1
Binding site 1 of hPRL has generally been
assigned to the section bordered by helix 1, helix
4, and the second half of loop 1. Alanine scanning
mutagenesis of loop 1 residues5 and of residues in
helix 1 and helix 46,9 as determined using PRL from
either human or rat, has identified 13 residues as
important for site 1 binding. For helix 1, Val23,
His30 and Phe37 could be demonstrated to be
important for receptor binding while for helix 4,
Tyr169, His173, Arg176, Arg177, His180, Lys181,
Tyr185 and Lys187 significantly altered both bind-
ing affinities and biological function. Loop 1
residues involved are His59, Pro66 and Lys69. The
proposed site 1 receptor-binding site of PRL is
shown in Figure 6(a). It is seen that aromatic
residues, together with large hydrophobic and
polar residues with many positive charges occupy
the concave binding site, complementing the
tryptophan and negatively charged residues of the
receptor hot spots.35 Pro66 is not accessible to
solvent, and Val23 and His59 are distal to the
otherwise joint location of all of the remaining site 1
residues which, as suggested by earlier studies,
confirm the relatively limited biological importance
of these three residues.6 The remaining ten residues
form a convincing receptor binding site. It could be
further speculated that His27, Asn184, and Leu188
play a significant role in receptor binding as well.
Although His27 in both bovine and human PRL has
been found not to be important for bioactivity,36,37
proteins mutated at Asn184 display up to 50%
lower bioactivity.6 The three residues are close to
the binding site and are solvent accessible.
Binding site 2
A hydrophobic channel is formed between helix 1
and helix 3 that outlines the second receptor
binding site in hPRL. This site has been described
as a flat binding surface that does not have distinct
hot spots of residues responsible for most of the
binding free energy. The affinity of binding site 2 for
a receptor molecule is significantly lower than the
affinity of site 1. Upon binding of a receptor
molecule at site 1, the affinity for binding of a
second receptor molecule is substantially increased
approaching the affinity of site 1.2,19 From muta-
genesis studies, Ala22, Arg21, Tyr28, Arg125 and
Gly129 were shown to be important for receptor
binding.9,29,36,38 Inspection of the putative binding
site from an early structural model of PRL
suggested a set of small residues to be important
for maintaining the geometry of the site.39 The
suggested site 2 receptor-binding site is shown in
Figure 6(b), and from inspection of the architecture
of this site, it is clear that a very hydrophobic
channel is indeed observed, the base of which is
formed mainly by the small Ala22 and Gly129, as
Figure 6. Suggested receptor
binding sites 1 and 2 of hPRL.
(a) Residues determined from
earlier mutagenesis work are out-
lining the receptor-binding site 1
and are colored red. A subset of
the residues are distant to the
common binding site or not sol-
vent accessible (not observable in
the present display) and are
colored blue (Val23, His59,
Pro66). Residues that are specu-
lated from this work to be
involved in receptor recognition
are Asn184 and Leu188 and are
colored yellow. (b) Residues out-
lining the hydrophobic channel of
receptor binding site 2 are shown
in red space-filled atoms and the
two small residues Ala22 and
Gly129 structuring the floor of the
channel are shown in white space-
filled atoms. Tyr28, known from
earlier work to be important for
receptor interaction is shown in
orange space-filled atoms, and
residues outside the channel
investigated in earlier mutagenesis
studies are shown in yellow space-
filled atoms. For both (a) and (b) a
smooth ribbon drawn through the
backbone atoms is shown in grey
and residues not shown in color
are shown as a surface represen-
tation.
Structure of Prolactin 819pinpointed in earlier studies29,38 flanked by Leu126
and Ile133 at each side. The side-chains of Leu18,
Arg21, Leu25, Arg125, Glu128 and Leu132 make up
the interior wall of the hydrophobic channel, and
the rim of the channel is extended by the inclusion
of Tyr28 on one side. The residues scanned in earlier
studies29 are positioned upstream compared to the
hydrophobic channel, which may explain the
modest effects observed in the alanine scan. This
displacement of binding site 2 was already recog-
nized in 1996 from a thorough description of the
lactogenic sequence–function relationships.40 Our
results indicate that the source of the increased
affinity of site 2 upon binding a receptor molecule at
site 1 is not due to conformational changes in hPRL.
A major contribution to the binding of the ternary
complex may stem from receptor–receptor inter-actions, as described in detail through mutation
analysis for the ternary hGH–hGHR complex.41,42
The N-terminal residues of oPL have been
suggested to play a critical role in receptor binding
to site 2, based on the identification of hydrogen
bonds.25 Iterative truncation of the first 13 residues
of hPRL either had no effect on the biological
function, or if any, improved the biological
activity.10,43 The removal of the N-terminal
residues, however, does abolish the residual
agonistic activity of the G129R antagonist.10,43 The
N-terminal residues of GH do not contain crucial
binding determinants for binding to the PRL
receptor.8 As removal of the first 14 N-terminal
residues of PRL reduced affinity and decreased
bioactivity, this suggests a critical role of Thr14,
either in receptor binding or in stabilizing helix 1. In
820 Structure of Prolactinthe present structure, Thr14 forms an N-terminal
capping motif with the side-chain of Asp17, which
clearly explains the destabilizing effect of removing
this residue. The role of the extended N terminus of
PRLs is more likely to promote zinc-dependent PRL
aggregation or some other activity of hPRL as
previously suggested.43,44
The growth hormone–prolactin receptor
interaction
In GH, residues in the first mini-helix, especially
Phe44, together with the C-terminal residues of
helix 2 and the N-terminal portion of helix 4, have
been shown to be important for hPRLR binding, but
have no effect on binding to hGHR.45 Mutation of
what was believed to be a corresponding residue in
hPRL, Phe50, has almost no effect on hPRLR
binding.46 However, based on the present structure
of hPRL, Phe44GH and Phe50PRL do not align
structurally (Figure 5(b)). Instead, Ile55 of hPRL is
more likely the residue comparable to Phe44 of
hGH. This may explain why no effect was observed
for the Phe50 mutant. It was also suggested that for
hGH, residues of the first mini-helix couple binding
at site 1 to structural changes in site 2 mediated by
residues Phe44, Leu93, Tyr160, Tyr164 and
Leu163.47,48 No similar effect has been identified
for hPRL, although deletion of residues Asp41–
Thr52 decreased the lactogenic activity by a factor
of 14,000. This, however, also shifted the tryptophan
fluorescence to higher wavelengths, an indication of
decreased protein stability.46 The residues of hPRL
corresponding to GH coupling residues are Ile55,
Leu98, Tyr169, Leu172, and His173. Many of these
residues are deeply buried, suggesting that large
structural changes are likely to occur when
substituted with the charged residue glutamate, as
done for hGH.
Several studies have pointed to marked differ-
ences in receptor binding between hGH, oPL, and
hPRL, both in terms of specificities and affinities.
One explanation for the promiscuity of hGH in
receptor preference compared to PRL may be
sought in the absence of the mini-helix in the
beginning of the loop separating helix 1 and helix 2
in hPRL and oPL. Thus, for the lactogenic activity of
hGH, partial unravelling of the mini-helix is a
prerequisite for correct presentation of the residues
interacting with hPRLR, especially of Phe44. This
built-in structural plasticity of hGH in this particu-
lar structural segment has been documented by
several studies pointing to high flexibility in this
area.27,49 This flexibility may not be present in PL or
PRL. We suggest that this mini-helix forms the basis
for the promiscuity of hGH in its receptor inter-
action preferences.Conclusions
Here, we have shown that the structure of hPRL
in solution is highly similar to that of both oPLbound to rPRLR and hGH in various complexes. It
is thus unlikely that any major structural rearrange-
ment occur upon receptor binding. Significant
differences in loop structures are found between
the lactogenic and the somatotropic hormones.
Although the binding of hPRL to hPRLR differs
from the binding of hGH to hPRLR by the hot spot
residues of the binding sites, it is proposed that
intrinsic flexibility in the first overhand connection
in hGH is a prerequisite for the broader receptor
preference of the growth hormones. We have also
shown that the present structure of hPRL con-
vincingly confirms the positioning of both binding
sites 1 and 2 obtained earlier from a large set of
mutagenesis data. We have shown that hPRL and
hPRLR-ECD forms a tight 1:1 complex but also that
an apparent 1:2 complex can be formed with a
stability that allows its detection by gel filtration.
A significant finding emerging from this study is
that the increased affinity for PRLR at the second
receptor binding site of PRL when the first site is
occupied does not result from an induced confor-
mational change, but likely results from receptor–
receptor interaction. This observation will both
direct further experiments and provide a new
perspective from which to view the substantial
body of biochemical data on PRL–PRLR interaction.MethodsPurification of recombinant human prolactin
hPRL, both unlabeled, 15N-labeled, (13C,15N)labeled,
and [13C]leucine-labeled was expressed in Escherichia coli
BL21(DE3) from the pT7-hPRL vector as described.6,50
The protein was refolded from inclusion bodies by
continuous dialysis at a protein concentration !0.1 mg/
ml into 20 mM NH4HCO3, 0.2 M NaCl (pH 8) (40 l,
48 hours). Monomeric hPRL was purified using gel
filtration on a Sephadex G-100 column, with 20 mM
NH4HCO3, 0.05 M NaCl (pH 8), and reduced hPRL was
removed using aHiTrapQ-Sepharose column,with 20 mM
Tris–HCl (pH 8.0) and a NaCl gradient from 0–0.5 M.NMR samples
Samples of [15N]hPRL, [13C,15N]hPRL and [13C]leucine-
hPRL at a protein concentration of approximately 1 mM
were prepared in 2 mMNH4HCO3 (pH8), 10% (v/v)
2H2O.
A sample of 1 mM 13C,15N-hPRL in 100% 2H2O, 2 mM
NH4HCO3 (pH8),was also prepared. Formeasurements of
residual dipolar couplings (RDCs) a partly aligned
sample was prepared by addition of phage Pf1 to 0.
7 mM [13C,15N]hPRL in 2 mM NH4HCO3 (pH 8), 20%
2H2O. The phage resulted in a splitting of 6.5 Hz of the
2H2O signal corresponding to a phage concentration of
6.5 mg/ml. A matched isotropic sample of 0.7 mM
[13C,15N]hPRL in 2 mM NH4HCO3 (pH 8), 20%
2H2O
was also prepared. For comparison to data by Keeler
et al.,20 a sample of [13C,15N]hPRL in 100 mM NaCl (pH
6.8), 10% 2H2O was prepared.
Structure of Prolactin 821Purification of the extracellular domain of recombinant
prolactin receptor, hPRLR–ECD
The sequence of the extracellular domain of the human
prolactin receptor (hPRLR-ECD) was extracted from a
cDNA library and fused to a C-terminal hexa-His-tag
(hPRLR(Met0-Asp210)-GSRS-His6). This construct was
expressed in E. coli BL21(DE3) cells from the pQE70
vector and refolded from inclusion bodies by simple
dialysis into 50 mM Tris–HCl (pH 9.0), 150 mM NaCl,
10 mM cysteamin, 1 mM cystamin (3!4 l), protein
concentration !0.1 mg/ml. The refolded fraction was
precipitated by addition of ammonium sulfate to 75%
(w/v), and left for two hours with gentle stirring at room
temperature. The precipitate was dissolved in MilliQ
water and gel-filtered on Sephadex G-100 in 30 mM
NH4HCO3, 0.1 M NaCl (pH 8). Peak fractions were
dialyzed against 20 mM Tris–HCl (pH 9.0). Reduced
hPRLR-ECD was removed by passing the sample over a
Q-Sepharose FF-column in 20 mM Tris–HCl (pH 9.0),
with a linear gradient from 0–1 M NaCl. The protein was
concentrated and buffer exchanged on spin-columns into
2 mM NH4HCO3, 10%
2H2O (pH 8.0).NMR spectroscopy
For assignment, all NMR spectra were recorded at
310 K on a Varian INOVA 800 with a 5 mm triple-
resonance probe equipped with a Z-field gradient. For
sequential assignment the following spectra were
recorded on the (13C,15N)labeled sample in 10% 2H2O:
HSQC, HNCO, HN(CA)CO, HNCA, HNCOCA, CBCA
CONH and HNCACB. For side-chain assignment C(CO)
NH, H(CCO)NH and HCCH-TOCSY spectra (with offsets
at both the aliphatic and aromatic resonances, respect-
ively) were recorded on the (13C,15N)labeled sample in
100% 2H2O. NOE assignments were based on a
15N-
NOESY-HSQC (recorded on the 15Nlabeled sample), a
13C-NOESY-HSQC of the aliphatic region and a 13C-
NOESY-HSQC of the aromatic region (both recorded on
the (13C,15N)labeled sample in 100% 2H2O). All of the
pulse-sequences were from the Varian Protein-Pack
version 1.6C. For measurement of NH RDCs the S3CT
experiment was applied.51 The spectra were processed
using nmrPipe.52 For comparison to the data by Keeler
et al.20 a 13C-NOESY-HSQC of the aliphatic region was
recorded at pH 6.8, 100 mM NaCl and 298 K.† http://www.rcsb.org/
‡ http://www.bmrb.wisc.edu/Assignment and structure calculation
Sequential and side-chain assignments were performed
manually using Pronto3D.53 Initially NOEs were assigned
automatically using the CANDID routine in Cyana.54 The
assignments obtained from CANDID were analyzed in
Pronto3D and peak-lists corrected prior to a new round of
automated NOE assignment. After several rounds of
automated NOE assignment, the NOE assignments were
finalised by several rounds of manual assignment. Final
structure calculations were performed in Xplor-NIH,55
including a conformational database potential56 and the
measured NH RDCs in the refinements. Two hundred
structures were calculated and from these 20 structures
with the lowest overall energy and fewest restraint
violations were chosen to represent the structure of
hPRL. Structures were visualized using MOLMOL57
and INSIGHTII (MSI) and structural alignments were
done using MODELLER v.6.2.58Hormone–receptor interaction studies
Titration studies of 15Nlabeled hPRL with unlabeled
hPRLR were performed at 298 K. Two samples were
prepared: (A) 40 mM hPRL, 2 mM NH4HCO3, 10%
2H2O
(pH 8.0) (1:0); and (B) 140 mM hPRLR, 40 mM hPRL, 2 mM
NH4HCO3, 10%
2H2O (pH 8.0) (1:3.5). Sample (B) was
added to sample (A) in aliquots resulting in NMR
samples with the following molecular ratios: 1:0–1:0.5–1:
1–1:1.4:–1:1.75–1:3.5 ([15N]hPRL:hPRLR-ECD) at a con-
stant concentration of 40 mMhPRL. 15N,1H-TROSY-HSQC
spectra were recorded on each sample. Assignments of
[15N]hPRL at 298 K were obtained by lowering the
temperature from 310 K in steps of 5 K and recording
H,15N-HSQC spectra at each temperature. Native PAGE
and SDS-PAGE were run on samples extracted from the
NMR samples at the different ratios of hormone and
receptor, including samples of unbound receptor.
Analytical gel filtration experiments of a set of samples
representing various ratios of hPRL:hPRLR were run on
Superdex 75 in 25 mM Tris–HCl (pH 8.0), 50 mM NaCl at
room temperature. Protein concentrations varied between
runs and were typically in the micromolar range. The
column was calibrated using standard markers, blue
dextran, and acetone, and the apparent partition coeffi-
cient, KAV, was calculated for all peaks.Data base deposits
Atomic coordinates and experimental NMR restraints
of human PRL have been deposited in the Protein Data
Bank, Research Collaboratory for Structural Bio-
informatics, Rutgers University, New Brunswick, NJ†
under the accession code 1RW5. Chemical shift assign-
ments for human PRL at pH 8.0 have been deposited in
BioMagResBank‡ with the entry number 6643.Acknowledgements
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